文献速递产科母胎医学

胎盘生长因子预测有早产型子痫前期症状或体征孕妇的分娩时间:一项前瞻性多中心研究

Placental growth factor predicts time to delivery in women with signs or symptoms of early preterm preeclampsia: a prospective multicenter study.
PubMed 文献 · Am J Obstet Gynecol · 2019-09-10

这项前瞻性多中心观察性研究纳入753例20.0至35.0周有子痫前期症状或体征的孕妇,检测就诊时胎盘生长因子并随访分娩时间。作者认为胎盘生长因子预测不良妊娠优于临床指标。

要点

  • 753例中538例(71%)最终诊断为子痫前期,542例(72%)在37周前分娩。
  • 胎盘生长因子正常者14天内子痫前期阴性预测值为90%,7天内为93%。

核心结论

  • 在<35.0周有子痫前期症状或体征的孕妇中,低胎盘生长因子与早产强烈相关,且不依赖于子痫前期诊断或就诊时孕周。
  • 正常胎盘生长因子与妊娠延长相关,即使患者最终诊断为子痫前期也是如此。
  • 作者认为胎盘生长因子在预测疑似子痫前期孕妇不良妊娠方面优于临床指标。

研究设计与样本

  • 前瞻性观察性研究,在24个中心纳入20.0至35.0周有子痫前期症状或体征的孕妇。
  • 就诊时采血检测胎盘生长因子,受试者按当地方案评估和治疗,最终诊断由独立专家小组根据2013年美国妇产科医师学会妊娠期高血压标准裁定。
  • 胎盘生长因子在Alere公司triage平台上回顾性检测,正常定义为>100 pg/mL,检测限为12 pg/mL。

主要发现

  • 共纳入753例,538例(71%)最终诊断为子痫前期,542例(72%)在<37周分娩,358例(47%)在<34周分娩。
  • 279例(37%)就诊时胎盘生长因子正常,其14天内子痫前期阴性预测值为90%,7天内为93%。
  • 胎盘生长因子正常(>100 pg/mL)、低(12-100 pg/mL)和极低(<12 pg/mL)者的分娩时间分布分离良好,中位数分别为45天、10天和2天。
  • 胎盘生长因子≤100 pg/mL者的围产儿死亡率为5.7%,小于胎龄儿率为51.7%;胎盘生长因子>100 pg/mL者的围产儿死亡率为0%(本队列中无观察病例),小于胎龄儿率为16.8%。

关键数值与推荐

  • 胎盘生长因子正常定义为>100 pg/mL,检测限为12 pg/mL。
  • 胎盘生长因子正常者14天内子痫前期阴性预测值为90%,7天内为93%。

临床怎么用

  • 作者认为胎盘生长因子在预测疑似子痫前期孕妇不良妊娠方面优于临床指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a robust association between altered angiogenic factor concentrations, which includes placental growth factor and clinically recognized preeclampsia. Alterations in concentrations of angiogenic factors precede the clinical onset of preeclampsia by several weeks. The temporal relationship between the measured angiogenic factors and the time to delivery in women with suspected preeclampsia at <35 weeks gestation, however, remains to be clarified. OBJECTIVE: The purposes of this study were to examine the relationship between placental growth factor and time to delivery in women at <35 weeks gestation with signs or symptoms of preeclampsia and to compare the performance of placental growth factor to other clinical markers for prediction of time to delivery in preeclampsia. STUDY DESIGN: Women with signs or symptoms of preeclampsia between 20.0 and 35.0 weeks gestation were enrolled in a prospective, observational study at 24 centers. Blood was collected at presentation for placental growth factor, and subjects were evaluated and treated according to local protocols. Clinical outcomes were obtained, and all final diagnoses were adjudicated by an independent expert panel according to 2013 American College of Obstetricians and Gynecologists' Hypertension in Pregnancy criteria. Placental growth factor was measured retrospectively on the Alere, Inc, triage platform. A normal placental growth factor was defined as >100 pg/mL; the assay's limit of detection is 12 pg/mL. Two-by-2 tables were constructed for comparison of test outcomes that included negative predictive value; time-to-delivery was analyzed by survival curves and Cox regression. RESULTS: Seven hundred fifty-three subjects were enrolled; 538 (71%) had a final diagnosis of preeclampsia; 542 (72%) delivered at <37 weeks gestation, and 358 (47%) delivered at <34 weeks gestation. Among the 279 women (37%) with a normal placental growth factor at presentation, the negative predictive value for preeclampsia delivered within 14 days or within 7 days was 90% and 93%, respectively. Compared with women with normal placental growth factor, women with placental growth factor ≤100 pg/mL have a hazard ratio of 7.17 (confidence interval, 5.08-10.13) in Cox regression for time to delivery after adjustment for both gestational age at enrollment and the final diagnosis of preeclampsia. The placental growth factor levels of normal (>100 pg/mL), low (12-100 pg/mL), and very low (<12 pg/mL) have well-separated distributions of time to delivery, with median values of 45, 10, and 2 days, respectively. Subjects with placental growth factor ≤100 pg/mL have a perinatal death rate of 5.7% and a small-for-gestational-age rate of 51.7%; subjects with placental growth factor >100 pg/mL have a perinatal death rate of 0% (no observations in this cohort) and an a small-for-gestational-age rate of 16.8%. CONCLUSION: In women with suspected preeclampsia at <35.0 weeks gestation, a low placental growth factor was correlated strongly with preterm delivery independent of a diagnosis of preeclampsia or gestational age at presentation, whereas a normal placental growth factor was associated with pregnancy prolongation, even in patients who ultimately had a final diagnosis of preeclampsia. This suggests that placental growth factor levels are superior to clinical markers in the prediction of adverse pregnancy in women with suspected preeclampsia.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Barton JR, Woelkers DA, Newman RB, et al. Placental growth factor predicts time to delivery in women with signs or symptoms of early preterm preeclampsia: a prospective multicenter study. Am J Obstet Gynecol. 2019. PMID: 31518550. doi:10.1016/j.ajog.2019.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。